Cue Biopharma, Inc. (CUE)
$
0.64
-0.01 (-1.56%)
Key metrics
Financial statements
Free cash flow per share
-0.4697
Market cap
47.5 Million
Price to sales ratio
5.9452
Debt to equity
1.0828
Current ratio
1.0279
Income quality
0.8554
Average inventory
0
ROE
-2.2843
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company that specializes in developing biologic drugs aimed at selectively modulating the human immune system to address a variety of health issues, including cancers, chronic infectious diseases, and autoimmune disorders. Its leading drug candidate, CUE-101, is a fusion protein biologic currently undergoing a Phase 1b clinical trial, which targets and activates antigen-specific T cells for treating cancers related to human papillomavirus. Additionally, the company offers CUE-102, a fusion protein biologic designed to activate antigen-specific T cells for cancer treatment, along with CUE-103, part of the CUE-100 series Immuno-STAT aimed at the KRAS G12V mutation relevant to colorectal carcinoma, lung cancer, and pancreatic cancer. CUE-200 targets cell surface receptors, including CD80 and/or 4-1BBL, to combat T cell exhaustion linked to chronic infections, while CUE-300 and CUE-400 are frameworks intended for various autoimmune diseases. The EBITDA is -$41,500,000.00 a key indicator of the company's operational profitability, and the gross profit stands at $6,937,000.00 highlighting the company's profitability from its core operations. The company’s income before tax is reported at -$40,674,000.00 showcasing its pre-tax profitability, and with total revenue at $9,287,000.00 it indicates the niche market focus. Furthermore, the total operating expenses amount to $50,787,000.00 encompassing a variety of incurred operational costs. The company's stock is affordable at $0.64 making it suitable for budget-conscious investors. With an average trading volume of 177,241.00 the stock exhibits moderate liquidity, facilitating trading activities. Additionally, the company holds a market capitalization of $48,073,236.00 categorizing it as a small-cap player in the financial landscape. As a key player in the Biotechnology industry, Cue Biopharma significantly contributes to the overall market dynamics, actively driving innovation and growth in its field. It is classified under the Healthcare sector, reflecting its strategic position in the biopharmaceutical industry while working towards advancements in immunology and targeted therapies.
Is Cue Biopharma, Inc. (CUE) a good investment?
Investing in Cue Biopharma, Inc. (CUE) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bearish outlook. Always conduct your own research before investing.
What is Cue Biopharma, Inc. (CUE)'s stock forecast?
Analysts predict Cue Biopharma, Inc. stock to fluctuate between $0.45 (low) and $1.99 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Cue Biopharma, Inc.'s market capitalization?
As of 2025-05-30, Cue Biopharma, Inc.'s market cap is $48,073,236, based on 75,349,900 outstanding shares.
How does Cue Biopharma, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Cue Biopharma, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Cue Biopharma, Inc. (CUE) stock?
To buy Cue Biopharma, Inc. (CUE) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CUE. Place an order (Market, Limit, etc.).
What is the best time to invest in Cue Biopharma, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Cue Biopharma, Inc. perform in the last earnings report?
Revenue: $9,287,000 | EPS: -$0.72 | Growth: -35.14%.
Where can I find Cue Biopharma, Inc.'s investor relations reports?
Visit https://www.cuebiopharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Cue Biopharma, Inc.?
You can explore historical data from here
What is the all-time high and low for Cue Biopharma, Inc. stock?
All-time high: $18.42 (2021-11-16) | All-time low: $0.45 (2024-09-24).
What are the key trends affecting Cue Biopharma, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
Ingelheim, Germany, and Boston, MA, USA, April 14, 2025 – Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma's CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases. Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the potential treatment of autoimmune and inflammatory diseases.
globenewswire.com
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the pricing of an underwritten public offering of (i) 13,530,780 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 3,382,695 shares of common stock and, (ii) to certain investors in lieu of common stock, pre-funded warrants to purchase 11,469,216 shares of common stock and accompanying common stock warrants to purchase an aggregate of 2,867,304 shares of common stock. Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $0.79, and each pre-funded warrant and accompanying common stock warrant are being sold together at a combined public offering price of $0.789. The aggregate gross proceeds of the offering are expected to be approximately $20 million, before deducting underwriting discounts and commissions and other offering expenses. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. Each common stock warrant will have an exercise price of $0.79 per share, will be exercisable immediately and will expire five years from the date of issuance. The offering is expected to close on or about April 16, 2025, subject to satisfaction of customary closing conditions. All of the securities are being offered by Cue Biopharma.
globenewswire.com
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Cue Biopharma.
globenewswire.com
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it will host a conference call and webcast to provide a business update on Tuesday, April 15, 2025 at 4:30 p.m. ET.
globenewswire.com
INGELHEIM, Germany and BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma's CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases. Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the potential treatment of autoimmune and inflammatory diseases.
globenewswire.com
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- - Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today reported fourth quarter and full year 2024 financial results.
See all news
